IceCure Medical Posts 83% US Sales Growth in First Nine Months of 2026
IceCure Medical reports strong US momentum, with sales surging 83% year-over-year and commercial reach expanding to 21 states through September 2026.
IceCure Medical Ltd. (NASDAQ: ICCM), an Israel-based developer of minimally invasive cryoablation technology, reported an 83% year-over-year increase in U.S. sales for the nine months ended September 30, 2026, alongside a significant expansion of its commercial footprint across the United States.
The Caesarea-based company said its ProSense system, which destroys tumors by freezing rather than surgical removal, is now available in 21 U.S. states, marking what the company characterized as major growth in its domestic commercial reach. The figures cover the first three quarters of the company's fiscal year.
Read more Three California Counties Drove Two-Thirds of State Rideshare Trips →
Cryoablation, the technology underlying IceCure's platform, is used as a minimally invasive alternative to conventional surgery for certain tumor types. The company's expansion strategy has focused on broadening access to the procedure across American healthcare markets.
The results signal accelerating adoption of non-surgical tumor treatment options in the U.S. market, as providers and patients increasingly seek alternatives to open surgery. IceCure's geographic expansion to 21 states reflects a deliberate push to deepen its U.S. commercial infrastructure heading into the final quarter of the year.
Continue reading at Earnings for the full financial breakdown and management commentary.